A&Z Pharmaceutical, LLC Enters into a Distribution and Marketing Agreement with Arctic Ease, LLC
October 2009 —Pittsburgh, PA
A&Z Pharmaceutical, LLC has secured an exclusive distribution and marketing agreement with Arctic Ease, LLC to represent their products in the Middle East and other select countries in South America and Europe.
Arctic Ease, LLC is a Pennsylvania based company established for the manufacture and sales of FDA approved cryotherapy wraps and pads. The company’s products involve a patent pending treated textile that is used to ease swelling and pain due to sprains, insect bites, muscle cramps, headaches, degenerative joint diseases, and more. The products offer the institutional and self-care markets the ability to treat soft tissue injuries and burns in a painless, convenient, and cost effective manner.
This ground-breaking technology is just entering the U.S. market for military and personal use, and now, through partnership with A&Z, will be made available in the Middle East. The wraps are non-toxic, latex free, biodegradable, “green” and safe for the environment. They are designed to maintain effective cooling of the affected area over an extended period of time without restricting the users’ mobility.
A&Z Pharmaceutical Partners with Innovative Wound Care Company
October 2009 —Pittsburgh, PA
Wound Management Technologies, Inc., (OTC BB: WNDM) a rapidly growing provider of specialty medical products, announced today an agreement with Pharma Technology International, LLC to market, distribute and sell the company’s wound care products in the Middle East.
The initial focus will be on Wound Management Technologies’ major product, CellerateRx®, which is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx’s patented collagen fragments, which are a fraction of the size of the native collagen molecules and particles found in other products, deliver the benefits of collagen to the body immediately.
Wound Management Technologies CEO, Scott Haire, said, “This agreement with Pharma Tech represents an important expansion of our sales activities by opening the strategic Middle East region. Pharma Tech has strong marketing operations and deep distribution channels, which strengthen our expectation for excellent results from this new association.”
About Pharma Technology International, LLC
Pharma Technology International, LLC is a joint venture partnership between BioPharma Technologies, Inc. (a subsidiary of Wound Management Technologies, Inc.) (OTC BB: WNDM) and A&Z Pharmaceutical, LLC, to exclusively license, market, distribute and sell Wound Management Technologies’ line of activated collagen-based products, all FDA cleared as medical devices and for use in the management of chronic and acute wounds and skin ulcers. Click here to be directed to the Pharma Technology International, LLC Web site.
About A&Z Pharmaceutical, LLC
A&Z Pharmaceutical, LLC is a privately held wholesale distributor of pharmaceuticals headquartered in Pittsburgh, PA. Through direct contracts with manufacturers, A&Z provides its customers with top-rated pharmaceuticals and medical products at competitive wholesale prices. Since its inception in 1997, A&Z Pharmaceutical, LLC has been selective in targeting its customers, which include tertiary hospitals, medical institutions, and governmental agencies located in the United States, South America, Europe, and the Middle East. For more information, visit http://www.azpharm.com/html/about.htm.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. The company’s corporate headquarters are in Fort Worth, Texas. For more information please visit the company's Website at www.celleraterx.com.
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
A&Z Pharmaceutical, LLC Enters into an Exclusive Distribution and Marketing Agreement with Hypertension Diagnostics, Inc.
August 2009 —Pittsburgh, PA
CVProfiler—the product that offers the physician the ability to quickly evaluate patient cardiovascular systems in the office or medical clinic!
A&Z Pharmaceutical has secured an exclusive distribution and marketing agreement with Hypertension Diagnostics, Inc. (HDI), a Minnesota based company, to represent its CVProfiler product in the M.E.N.A. (Middle East North Africa) region to include the countries of Algeria, Bahrain, Egypt, Jordan, Kuwait, Lebanon, Morocco, Oman, Qatar, Saudi Arabia and United Arab Emirates.
CVProfiler is an FDA approved non-invasive profiling system that detects early signs of cardiovascular disease by collecting blood pressure wave form data produced with each heart beat. The CVProfilor establishes both large and small artery elasticity indices. Premature loss of arterial elasticity or flexibility has been shown extensively in medical literature to be correlated with both macro- and micro-vascular alterations which progress to cardiovascular morbidity and mortality.
For additional information on HDI and the CVProfiler, click here.
NEW from A&Z!
Homeopathic Remedies for Horses, Pets, and Sporting Animals
December 2007—Pittsburgh, PA
A&Z Pharmaceutical, LLC recently entered into an agreement with N.E.T. Remedies® to be the exclusive distributor of their homeopathic remedies to the Middle East, with a primary focus on equine and sporting animal health. Products available at this time promote bronchial and digestive health, address emotional trauma, allow the body to recover from muscular and joint discomfort, and provides healing of scars, adhesions, and other skin disorders.
Each ingredient in the N.E.T. Remedies formulas is potentized to the 10x, 30x and 100x levels, allowing the body to use different potencies at different levels of the healing process. Thus, multiple potencies provide a broader therapeutic spectrum.
NET Remedies® formulas cannot inflict injury or harm in any form of side effects. Homeopathic remedies are compatible with nutritional supplements, herbs, and medicines. Due to the dramatic changes in our environment, NET Remedies® formulas offer effective answers for the demands today's health needs. NET Remedies® have made the normal course of care much easier, safer and faster for the patient.
A&Z Pharmaceutical, LLC has expanded its product line to include health and nutritional products for use with horses and other livestock. Organic Aloe Flakes and Aloe Derm topical cream are now available by exclusive contractual agreement with our US manufacturer. Several homeopathic remedies will soon be available.
